Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL 
    		2015 ASCO Annual Meeting
    	
    	
    	
    
        Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).
    
    
    
    
       
       
    		Anil D’Cruz, MD
		
		
        
		
		
		
		Anil D’Cruz, MD, of Tata Memorial Hospital, discusses results from his study that seem to resolve a 50-year-long debate on performing elective neck dissection at the time of primary surgery––a potentially practice-changing finding (Abstract LBA3).
			
			
     	
    
       
       
    		Asher Alban Chanan-Khan, MD, and James O. Armitage, MD
		
		
        
		
		
		
		James O. Armitage, MD, of the University of Nebraska Medical Center, and Asher Alban Akmal Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discuss an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).
			
			
     	
    
       
       
    		Maura N. Dickler, MD and Clifford A. Hudis, MD
		
		
        
		
		
		
		Clifford A. Hudis, MD, and Maura N. Dickler, MD, of Memorial Sloan Kettering Cancer Center, discuss adding bevacizumab to letrozole as a first-line endocrine therapy for treatment of hormone receptor–positive advanced breast cancer (Abstract 501).
			
			
     	
    
       
       
    		Jedd Wolchok, MD, PhD, and Anthony J. Olszanski, RPh, MD
		
		
        
		
		
		
		Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).
			
			
     	
    
       
       
    		Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD
		
		
        
		
		
		
		Chloe Evelyn Atreya, MD, PhD, of the University of California, San Francisco, talks with Axel Grothey, MD, of the Mayo Clinic, about new data on trametinib, dabrafenib, and panitumumab in patients with the BRAF V600E mutation and vemurafenib plus irinotecan and cetuximab in BRAF-mutated metastatic colorectal cancer (Abstracts 103 and 3511).